All articles tagged with #sildenafil
A study led by the Weizmann Institute of Science suggests sildenafil (Viagra) may prevent cancer cells from spreading by causing cholesterol to accumulate in recycling compartments, depriving tumors of cholesterol needed for invasion; while promising, clinical trials are needed to confirm it can reduce metastasis in patients.
Medicines often find new uses after their initial purpose; sildenafil, finasteride, and minoxidil were repurposed from heart, prostate, and blood-pressure indications to treat erectile dysfunction and hair loss, illustrating how serendipity and careful observation drive medical progress and highlighting the benefits and caveats of drug repurposing in men's health.
A Delphi-consensus by 21 experts named sildenafil (Viagra), Zostavax, and riluzole as the leading repurposed drug candidates for Alzheimer's prevention and treatment, highlighting their potential mechanisms and the need for rigorous clinical trials before any approved use.
A panel of researchers identified three approved medicines with potential to prevent or treat Alzheimer’s disease: the shingles vaccine (Zostavax), sildenafil (Viagra), and riluzole. These drugs target relevant Alzheimer’s mechanisms, have safety profiles suitable for older adults, and show promising results in cell/animal studies, prompting calls for robust clinical trials to determine true benefit and establish whether they can slow or prevent dementia.
A Chinese study suggests that sildenafil, commonly known as Viagra, may have potential in cancer treatment by enhancing immune cells that fight tumors, offering a new avenue for tumor immunotherapy.
A study suggests that Viagra (sildenafil) may help increase bone cell production and prevent bone loss, potentially offering a new treatment for osteoporosis in older adults, with additional benefits like reducing dementia risk.
New research suggests that sildenafil, the active ingredient in Viagra, may help reduce the risk of developing Alzheimer's disease. Studies have shown a potential link between sildenafil use and a decreased likelihood of Alzheimer's diagnosis, with some evidence indicating its ability to promote neuron growth and reduce the accumulation of toxic proteins. While further clinical trials are needed to confirm its effectiveness, researchers believe these findings warrant larger-scale investigations into sildenafil as a potential treatment for Alzheimer's.
A new observational study suggests that taking sildenafil, the active ingredient in Viagra, may lower the risk of developing Alzheimer's disease. However, unanswered questions remain, and more research is needed to understand the potential link and physiological mechanism. The study included an analysis of insurance claims data from over 2 million patients with pulmonary arterial hypertension, revealing a lower risk of Alzheimer's among those taking sildenafil. Lab experiments also showed potential benefits, but experts emphasize the need for well-designed clinical trials to provide a robust evidence base for considering sildenafil as a potential treatment for Alzheimer's disease.
A new study suggests that sildenafil, the main ingredient in Viagra, may reduce the risk of developing Alzheimer's disease. The research observed a 30% to 54% reduction in Alzheimer's incidence among people taking sildenafil for erectile dysfunction or pulmonary arterial hypertension. Lab research also found that sildenafil lowered levels of neurotoxic tau proteins and promoted improved brain function. However, experts caution that further exploration and clinical trials are needed to determine if sildenafil can effectively treat Alzheimer's, and warn against using such medications without consulting a physician.
A new study suggests that sildenafil (Viagra) may reduce the prevalence of Alzheimer's disease (AD) by 30%-54%, based on real-world patient data and mechanistic studies. The research, led by Feixiong Cheng, PhD, director of the Cleveland Clinic Genome Center, indicates that sildenafil could potentially be repurposed as a treatment for AD, supported by its ability to decrease neurotoxic protein levels in brain cells. The findings provide evidence for further clinical trials to examine the effectiveness of sildenafil in patients with Alzheimer's disease.
A new study led by the Cleveland Clinic suggests that sildenafil, the main component of Viagra, shows potential as a treatment for Alzheimer's disease. The research, which integrates computational models, insurance claims data, and laboratory observations, indicates a 30-54% reduction in Alzheimer's diagnoses among sildenafil users and decreased levels of neurotoxic proteins in brain cells. This interdisciplinary approach highlights the benefits of drug repurposing and offers a promising avenue for new Alzheimer's therapies, with implications for future clinical trials to explore sildenafil's effectiveness in patients with Alzheimer's disease.
New research led by the Cleveland Clinic suggests that sildenafil, the main component of Viagra, could be repurposed as a potential treatment for Alzheimer's disease. The study utilized computational models, insurance claims data, and observations from brain cells in Alzheimer's patients to provide evidence supporting sildenafil's potential therapeutic effects. The findings indicate a reduced prevalence of Alzheimer's disease diagnoses among patients who took sildenafil, and demonstrate its ability to lower levels of neurotoxic tau proteins and promote processes known to protect against neural degeneration. The research highlights the feasibility of using computer models to identify new drug candidates and provides evidence for further clinical trials to examine the effectiveness of sildenafil in Alzheimer's disease treatment.
A study from the UK suggests that erectile dysfunction drugs like sildenafil (Viagra) may be linked to a reduced risk of Alzheimer's disease. While the findings don't establish a cause-and-effect relationship, they warrant further clinical trials. The study analyzed data from over 269,000 older male residents and found that those taking a PDE5I were about 18% less likely to develop Alzheimer's compared to those who didn't. The potential protective effect of these drugs against Alzheimer's warrants further investigation, including randomized control trials to comprehensively understand their therapeutic benefits.
A 32-year-old man from Iran lost vision in one eye after taking a high dose of sildenafil, the main ingredient in Viagra. Doctors suspect that the erectile dysfunction medication may have caused the damage to his eye's blood vessels. Scans revealed clots in the artery and vein that transferred blood to and from his right eye, leading to swelling of the retina and macular edema. The pressure from fluid build-up eventually caused the retina to detach. While eye problems have been reported with sildenafil use, the exact link remains controversial. Further investigations are needed to understand the potential risks, particularly for younger men.